T2 Biosystems, Inc. 4
4 · T2 Biosystems, Inc. · Filed Aug 14, 2014
Insider Transaction Report
Form 4
AISLING CAPITAL III LP
10% Owner
Transactions
- Purchase
Common Stock
2014-08-12$11.00/sh+454,545$4,999,995→ 2,523,300 total(indirect: See footnote) - Conversion
Common Stock
2014-08-12+2,068,755→ 2,068,755 total(indirect: See footnote) - Conversion
Series E Convertible Preferred Stock
2014-08-12−549,851→ 0 total(indirect: See footnote)Exercise: $0.00→ Common Stock (323,441 underlying) - Conversion
Series D Convertible Preferred Stock
2014-08-12−2,967,033→ 0 total(indirect: See footnote)Exercise: $0.00→ Common Stock (1,745,313 underlying)
Footnotes (2)
- [F1]The preferred stock is convertible at any time, at the holder's election and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering.
- [F2]The reportable securities are owned directly by Aisling Capital III, LP ("Aisling"), and held indirectly by Aisling Capital Partners III, LP ("Aisling GP"), as general partner of Aisling, Aisling Capital Partners III LLC ("Aisling Partners"), as general partner of Aisling GP, and each of the individual managing members of Aisling Partners. The individual managing members (collectively, the "Managers") of Aisling Partners are Dennis Purcell, Dr. Andrew Schiff and Steve Elms. Aisling GP, Aisling Partners and the Managers share voting and dispositive power over the shares directly held by Aisling.